Kanada - Ingliż - Health Canada

teva canada limited - cephalexin (cephalexin monohydrate) - tablet - 250mg - cephalexin (cephalexin monohydrate) 250mg - first generation cephalosporins

Kanada - Ingliż - Health Canada

pharmascience inc - cephalexin - tablet - 250mg - cephalexin 250mg - first generation cephalosporins

Kanada - Ingliż - Health Canada

pharmascience inc - cephalexin - suspension - 250mg - cephalexin 250mg - first generation cephalosporins

Kanada - Ingliż - Health Canada

lupin pharma canada limited - cephalexin (cephalexin monohydrate) - powder for suspension - 250mg - cephalexin (cephalexin monohydrate) 250mg - first generation cephalosporins

Kanada - Ingliż - Health Canada

lupin pharma canada limited - cephalexin (cephalexin monohydrate) - tablet - 250mg - cephalexin (cephalexin monohydrate) 250mg - first generation cephalosporins

Kanada - Ingliż - Health Canada

sanis health inc - cephalexin (cephalexin monohydrate) - tablet - 250mg - cephalexin (cephalexin monohydrate) 250mg - first generation cephalosporins

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cefalexin monohydrate -

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cefalexin -

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - cefalexin monohydrate, quantity: 550 mg (equivalent: cefalexin, qty 500 mg) - capsule, hard - excipient ingredients: lactose monohydrate; magnesium stearate; gelatin; titanium dioxide; iron oxide yellow; brilliant blue fcf; sunset yellow fcf; purified water; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of the following bacterial infections when caused by susceptible strains of the designated micro-organisms. respiratory tract infections; strep. pneumoniae and group a b-haemolytic streptococci. although penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections (including the prophylaxis of rheumatic fever), cephalexin is generally effective in the eradication of streptococci from the nasopharynx. substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present. bacterial sinusitis: streptococci, strep. pneumoniae and staph. aureus (methicillin sensitive only). otitis media: strep. pneumoniae, staphylococci (methicillin sensitive only). skin and skin structure infections: staphylococci (methicillin sensitive only) and/or streptococci. genitourinary tract infections, including acute prostatitis: e.coli, p.mirabilis, and klebsiella sp. the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin rbx is not indicated in these conditions. note. appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin rbx. renal function studies should be perfomed when indicated.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - cefalexin monohydrate, quantity: 275 mg (equivalent: cefalexin, qty 250 mg) - capsule, hard - excipient ingredients: lactose monohydrate; magnesium stearate; gelatin; titanium dioxide; iron oxide yellow; brilliant blue fcf; sunset yellow fcf; purified water; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of the following bacterial infections when caused by susceptible strains of the designated micro-organisms. respiratory tract infections: strep. pneumoniae and group a b-haemolytic streptococci. although penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections (including the prophylaxis of rheumatic fever), cephalexin is generally effective in the eradication of streptococci from the nasopharynx. substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present. bacterial sinusitis: streptococci, strep. pneumoniae and staph. aureus (methicillin sensitive only). otitis media: strep. pneumoniae, staphylococci (methicillin sensitive only). skin and skin structure infections: staphylococci (methicillin sensitve only) and/or streptococci. genitourinary tract infections, including acute prostatitis: e.coli, p.mirabilis, and klebsiella sp. the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin rbx is not indicated in these conditions. note. appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin rbx. renal function studies should be perfomed when indicated.